No Data
No Data
RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87
Express News | Intra-Cellular Therapies Inc : UBS Raises Target Price to $87 From $79
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
US Manufacturing Index Rises To 43, Highest Since 2020